ResearcherKurume UniversityActive in the last 2 years
Toru Hisaka
Matched on OpenAlex author ID A5079874440, A5109491567. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 39
2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 7
- Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
- [Pathological Complete Response to Chemotherapy in Four Cases of Pancreatic Cancer]. Last author PMID 40840912↗
- Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.gastha.2024.04.011↗
- A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
- Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15913↗
- Neoplastic spindle cells are an independent prognostic factor in pancreatic cancer. First author DOI 10.1097/mpa.0000000000000337↗
- Metastatic pulmonary adenocarcinoma 13 years after curative resection for pancreatic cancer: report of a case and review of Japanese literature. Co-author DOI 10.6092/1590-8577/739↗
Closest collaborators
The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Susumu Eguchi · 2 shared papers, 2023–2026 · strength 0.37
- Paper Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncur… DOI 10.1002/ags3.70090↗
- Paper A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderlin… DOI 10.1245/s10434-022-12566-1↗
- Hirokazu Noshirο · 2 shared papers, 2023–2026 · strength 0.37
- Paper Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncur… DOI 10.1002/ags3.70090↗
- Paper A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderlin… DOI 10.1245/s10434-022-12566-1↗
- Naoki Ikenaga · 2 shared papers, 2023–2026 · strength 0.37
- Paper Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncur… DOI 10.1002/ags3.70090↗
- Paper A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderlin… DOI 10.1245/s10434-022-12566-1↗
- Yoshinobu Okabe · 3 shared papers, 2012–2024 · strength 0.33
- Paper Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.gastha.2024.04.011↗
- Paper Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.15913↗
- Paper Metastatic pulmonary adenocarcinoma 13 years after curative resection for pancreatic cancer: report of a case and revie… DOI 10.6092/1590-8577/739↗
- Yoshiki Naito · 2 shared papers, 2022–2024 · strength 0.31
- Masanori Akashi · 1 shared paper, 2025 · strength 0.26
- Yasuhisa Mori · 1 shared paper, 2026 · strength 0.23
- Teijiro Hirashita · 1 shared paper, 2026 · strength 0.23
- Hiromitsu Hayashi · 1 shared paper, 2026 · strength 0.23
- Tomoharu Yoshizumi · 1 shared paper, 2026 · strength 0.23
- Masafumi Nakamura · 1 shared paper, 2026 · strength 0.23
- Hiroaki Nagano · 1 shared paper, 2026 · strength 0.23
- Hiroto Matsui · 1 shared paper, 2026 · strength 0.23
- Shingo Kozono · 1 shared paper, 2026 · strength 0.23
- Hirohisa Okabe · 1 shared paper, 2026 · strength 0.23
- Hirohisa Yano · 2 shared papers, 2015–2022 · strength 0.18
- Hironori Koga · 1 shared paper, 2024 · strength 0.17
- Takuji Torimura · 1 shared paper, 2024 · strength 0.17
- Takumi Kawaguchi · 1 shared paper, 2024 · strength 0.17
- Tõru Nakamura · 1 shared paper, 2024 · strength 0.17
- Takahiko Sakaue · 1 shared paper, 2024 · strength 0.17
- Hiroaki Nagano · 1 shared paper, 2023 · strength 0.15
- Kazuyoshi Nishihara · 1 shared paper, 2023 · strength 0.15
- Kousei Ishigami · 1 shared paper, 2023 · strength 0.15
- Masafumi Nakamura · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.